FDA
-
-
-
-
-
-
-
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
-
-
-
-
-
-
-
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025
-
-
-
-
-
-
-
Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025
-
-
-
-
-
-
-
Ascentage Pharma Announces Proposed Top-Up Placement
-
-
-
-
-
-
-
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
-
-
-
-
-
-
322,996 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

